Celltrion wins EU recommendation to expand Steqeyma’s pediatric indications

By Maekyung News Service

South Korean biopharmaceutical company Celltrion Inc. said Monday that its biosimilar Steqeyma (CT-P43), has received a positive recommendation from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) to expand its approved uses to children with Crohn’s disease and ulcerative colitis aged 2 and older.

The recommendation covers an expanded label for Steqeyma, a biosimilar of Johnson & Johnson’s autoimmune disease drug Stelara, whose active ingredient is ustekinumab. Final approval procedures remain.

The expansion would broaden Steqeyma’s treatment coverage in Europe to younger pediatric patients. The drug is already approved there for several conditions, including plaque psoriasis in adults and children, psoriatic arthritis in adults, and Crohn’s disease and ulcerative colitis in adults, as well as Crohn’s disease in children weighing at least 40 kilograms.

“We will complete the remaining approval procedures and expand our portfolio of interleukin inhibitors to strengthen our position in the global autoimmune disease market,” said a company official.

Stelara generated around $6.08 billion in sales last year. The global ustekinumab market was estimated at $18.67 billion in 2025, according to pharmaceutical market research firm IQVIA.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.